advertisement
Abstract #59421 Published in IGR 16-3
Original and Generic Latanoprost for the Treatment of Glaucoma and Ocular Hypertension: Are They Really the Same?
Golan S; Rosenfeld E; Shemesh G; Kurtz SClinical and Experimental Pharmacology and Physiology 2015; 42: 220-224
We compared the intraocular pressure (IOP)-lowering effect and safety profile of latanoprost (Xalatan(®) ) with its generic variant, Glautan (Unipharm, Israel) after 1 and 4 weeks of treatment by doing a a Randomized, prospective, crossover comparison included patients with open-angle glaucoma (OAG) or Ocular hypertension (OHT), either naïve or treated and well-controlled, who were attending our department between 05/2010-11/2012. After a 3-week washout period for the medicated subjects, the participants were randomized to 4 weeks of treatment with either Xalatan or Glautan once every evening and then, after a 3-week washout period, crossed over to the other treatment for an additional 4 weeks. Efficacy was expressed by ΔIOP at 3 designated hours of the day after 1 week and 1 month of treatment, and tolerability was determined by ocular side effects as reported by the patient in a questionnaire. Nineteen patients (mean age at initial diagnosis 66 ± 9 years, 14 females) were enrolled, of whom 17 had bilateral OAG and 2 had unilateral disease. Both drugs lowered IOP after one week and one month (P=0.06 and P=0.04 respectively) of treatment. Xalatan had a tendency of greater efficacy than Glautan both after 1 week and 1 month, but the difference was not statistically significant (P=0.69 and P=0.34 respectively). Drug safety was similar, but more ocular side effects were reported after treatment with Glautan (21 vs. 12 for Xalatan, P=0.06). This article is protected by copyright. All rights reserved.
Department of Ophthalmology, Tel Aviv Medical Center, affiliated to the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Full articleClassification:
11.4 Prostaglandins (Part of: 11 Medical treatment)
